{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:37:27Z","timestamp":1745469447591,"version":"3.40.4"},"reference-count":20,"publisher":"S. Karger AG","issue":"Suppl. 1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>Of 15,681 patients with hepatocellular carcinoma (HCC), 30% underwent transcatheter arterial chemoembolization with lipiodol (Lip-TACE) including infusion chemotherapy with lipiodol (Lip-TAI) for the initial treatment, and 58% underwent it for recurrent HCC according to the latest biannual report of the Liver Cancer Study Group of Japan (LCSGJ). Superselective Lip-TACE is considered to be indispensable to maximize the therapeutic effect (TE) and to minimize injury to the non-cancerous liver. The local recurrence rate of a single session Lip-TACE for HCC \u22645 cm in diameter ranged from 33 to 38% at 3 years. A pathologic study using resected specimens of 26 HCCs treated by Lip-TACE showed that the mean necrosis rates and frequency of complete necrosis in three groups, small (\u22643 cm, n = 6 HCCs), medium (3.1\u20135 cm, n = 10), and large size (\u22675.1 cm, n = 10) were 95, 87.1%; 68.4, 66.7%; 30, 0%, respectively. Namely, the smaller the tumor size, the higher the TE. However, Lip-TAI showed no correlation between TEs and tumor size. A comparative study between the pathologically proven necrosis rate on the maximum cut surface of the lesion and radiologic necrosis estimated by CT showed a significantly good correlation when the lipiodol-retained area was presumed necrotic, but a poor correlation when it was presumed a viable one. No correlation was seen between the pathologic necrosis rate and the decreased rate of the lesion treated by Lip-TACE assessed by WHO criteria. The modified version of the assessment criteria of the TE of treatment for liver cancer was proposed by the LCSGJ in 2009, using a 4-grade treatment effect with two factors of tumor necrosis and tumor regression.<\/jats:p>","DOI":"10.1159\/000315242","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T08:56:16Z","timestamp":1278579376000},"page":"135-141","source":"Crossref","is-referenced-by-count":10,"title":["Chemoembolization for Unresectable Hepatocellular Carcinoma in Japan"],"prefix":"10.1159","volume":"78","author":[{"given":"Kenichi","family":"Takayasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2010,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1872-034X.2007.00119.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1872-034X.2007.00216.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2803%2914964-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2802%2908649-X"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053%2Fjhep.2002.33156"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.gastro.2006.05.021"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2214%2FAJR.08.1368"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2214%2FAJR.08.1285"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00270-008-9468-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00270-001-0070-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jvir.2006.12.004"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2214%2FAJR.09.3308"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819941101%2974%3A9%3C2449%3A%3AAID-CNCR2820740910%3E3.0.CO%3B2-4"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jvir.2008.02.013"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00270-009-9711-7"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.24050"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jhep.2006.10.020"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.cgh.2007.04.021"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0708857"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016%2FS1470-2045%2808%2970285-7"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/315242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/315242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:28:30Z","timestamp":1745436510000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000315242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":20,"journal-issue":{"issue":"Suppl. 1","published-online":{"date-parts":[[2010,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000315242","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2010]]}}}